Redefining how the world approaches, prevents, and heals mental health disorders.
We are a biotechnology company pioneering mental health innovation. We are committed to developing more effective and potentially disease-modifying mental health treatments by researching both psychedelic and non-psychedelic compounds.
LEARN MORE
OUR PERSPECTIVE
Shortcomings of existing therapies
Current standard of care treatments are ineffective for millions worldwide.
Limited Efficacy
Slow onset – Up to 3 months or more for SSRIs to take full effect
Trial and error – Remission with first selected SSRI occurs only 30% of the time
Low response rate – Only 50% respond within 8 weeks and 33% become treatment-resistant
High relapse rate – Estimated that 40-60% of patients with SUD return to active addiction
Side Effects
Addiction – 10-15% of benzodiazepine users become addicted
Sexual dysfunction – 55% of patients on SSRIs experience sexual dysfunction
Weight gain – Depending on the drug, patients on SSRIs gain on average 16-24lbs over 12 months
Sleep – SSRIs interfere with sleep architecture, potentially complicating the sleep of depressed patients
Our unique approach
Compounds with prior evidence in humans
To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles.
Enabling platform technologies
Decentralized drug development
In addition to funding, our evolving companies have access to our deep domain expertise and operational backbone.
Learn more about our approach
OUR MODELWHERE WE’RE HEADED
Our technologies drive efficient drug discovery and improved treatment outcomes.
Our unique model combines funding with operational expertise to develop innovative and impactful CNS therapeutics.
OUR MODELNews & Insights
Articles
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders
atai Life Sciences, a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has acquired a…
Articles
Recognify Life Sciences to Commence Phase 2a Study in Cognitive Impairment Associated with Schizophrenia
Recognify Life Sciences, Inc., an atai Life Sciences platform company focused on developing treatments for cognitive impairment with initial efforts…
Articles
Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders
Perception Neuroscience, an atai Life Sciences company focused on developing innovative therapies in neuropsychiatric disorders, and Otsuka Pharmaceutical Co., Ltd.,…